Dubai, April 12 -- Habib Khorakiwala, Chairman of Indian pharmaceutical company Wockhardt, on Friday said 'Zaynich,' its medicine for multi-drug resistant infections, is set to get the US Food and Drug Administration (USFDA) approval next year.

Zaynich is a novel antibiotic developed to target multi-drug-resistant Gram-negative infections.

"We started our research programme 25 years ago. And today we have six drugs for multi-drug resistance," the Chairman of the Indian pharmaceutical company told ANI on the sidelines of the ongoing 'Global Justice- Love and Peace Summit' in Dubai.

"We are the most successful research company, in the world, in antibiotic research today.... I think our contribution is not only making the drug affordable ...